FDA Approves Embrace Hydrogel Embolic System for Peripheral Arterial Bleeds

Instylla, Inc. has received FDA approval for its Embrace Hydrogel Embolic System, expanding its clinical use to treat peripheral arterial bleeds in vessels measuring 6 mm or less. This medical device provides a non-surgical option for managing arterial bleeding by utilizing a water-based polyethylene glycol hydrogel to create sustained vessel occlusion. The approval is supported by evidence from the HALT clinical trial.